
CAR-T therapy could treat large B-cell lymphoma
Biotechnology company Miltenyi Biotec has announced encouraging results from its CAR-T therapy for patients with second-line, relapsed or refractory large B-cell lymphoma. Primary analysis of candidate zamtocabtagene autoleucel (zamto-cel) showed the therapy demonstrated significant and clinically meaningful superiority over chemoimmunotherapy. The candidate was evaluated in the DALY 2-EU trial, conducted… Read More

